Approval Year
| Substance Class |
Protein
Created
by
admin
on
Edited
Sat Dec 16 07:38:31 GMT 2023
by
admin
on
Sat Dec 16 07:38:31 GMT 2023
|
| Protein Type | MONOCLONAL ANTIBODY |
| Protein Sub Type | IGG1 |
| Sequence Origin | HUMANIZED MOUSE |
| Sequence Type | COMPLETE |
| Record UNII |
NTY9893GD0
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C20401
Created by
admin on Sat Dec 16 07:38:31 GMT 2023 , Edited by admin on Sat Dec 16 07:38:31 GMT 2023
|
||
|
FDA ORPHAN DRUG |
341111
Created by
admin on Sat Dec 16 07:38:31 GMT 2023 , Edited by admin on Sat Dec 16 07:38:31 GMT 2023
|
||
|
NCI_THESAURUS |
C129822
Created by
admin on Sat Dec 16 07:38:31 GMT 2023 , Edited by admin on Sat Dec 16 07:38:31 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1169956-08-4
Created by
admin on Sat Dec 16 07:38:31 GMT 2023 , Edited by admin on Sat Dec 16 07:38:31 GMT 2023
|
PRIMARY | |||
|
YY-109
Created by
admin on Sat Dec 16 07:38:31 GMT 2023 , Edited by admin on Sat Dec 16 07:38:31 GMT 2023
|
PRIMARY | |||
|
9590
Created by
admin on Sat Dec 16 07:38:31 GMT 2023 , Edited by admin on Sat Dec 16 07:38:31 GMT 2023
|
PRIMARY | |||
|
Ocaratuzumab
Created by
admin on Sat Dec 16 07:38:31 GMT 2023 , Edited by admin on Sat Dec 16 07:38:31 GMT 2023
|
PRIMARY | |||
|
CHEMBL2109665
Created by
admin on Sat Dec 16 07:38:31 GMT 2023 , Edited by admin on Sat Dec 16 07:38:31 GMT 2023
|
PRIMARY | |||
|
NTY9893GD0
Created by
admin on Sat Dec 16 07:38:31 GMT 2023 , Edited by admin on Sat Dec 16 07:38:31 GMT 2023
|
PRIMARY | |||
|
CHEMBL2109346
Created by
admin on Sat Dec 16 07:38:31 GMT 2023 , Edited by admin on Sat Dec 16 07:38:31 GMT 2023
|
PRIMARY | |||
|
C2524
Created by
admin on Sat Dec 16 07:38:31 GMT 2023 , Edited by admin on Sat Dec 16 07:38:31 GMT 2023
|
PRIMARY |
| From | To |
|---|---|
| 1_22 | 1_96 |
| 1_148 | 1_204 |
| 1_265 | 1_325 |
| 1_371 | 1_429 |
| 2_22 | 2_96 |
| 2_148 | 2_204 |
| 2_265 | 2_325 |
| 2_371 | 2_429 |
| 3_23 | 3_87 |
| 3_133 | 3_193 |
| 4_23 | 4_87 |
| 4_133 | 4_193 |
| 1_224 | 3_213 |
| 2_224 | 4_213 |
| 1_230 | 2_230 |
| 1_233 | 2_233 |
| Glycosylation Link Type | Site |
|---|---|
| N | 1_301 |
| N | 2_301 |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
increased antibody-dependent cell-mediated cytotoxicity (ADCC),
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Molecular Formula | CHEMICAL |
|
||||
| MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|